Literature DB >> 17377491

Mdm2 widens its repertoire.

Amanda S Coutts1, Nicholas B La Thangue.   

Abstract

The p53 tumor suppressor protein is a DNA damage responsive transcription factor that affects diverse cellular processes which include transcription, DNA synthesis and repair, cell cycle arrest, senescence and apoptosis. The Mdm2 oncoprotein is a primary regulator of p53, mediating p53 control via ubiquitin-dependent proteasomal degradation. During DNA damage, the interaction between p53 and Mdm2 is reduced, which allows p53 levels to accumulate. p53 activity is tightly controlled and regulated at a multiplicity of levels, and the importance of co-factors that influence p53 activity is becoming increasingly evident. Recent studies have highlighted the role of Mdm2 in the control of p53 co-factors. Thus, Mdm2 targets JMY, a p53 co-factor, for ubiquitin-dependent Mdm2 targets JMY, a p53 co-factor, for ubiquitin-dependent proteasomal degradation and in doing so overcomes the ability of JMY to augment the p53 response. These results define a new functional relationship between control of p53 activity and Mdm2, and suggest that transcription co-factors which facilitate the p53 response are important targets through which Mdm2 mediates its oncogenic activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377491     DOI: 10.4161/cc.6.7.4086

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  9 in total

1.  p53 and MDM2 are involved in the regulation of osteocalcin gene expression.

Authors:  Hankui Chen; Kevin Kolman; Natalie Lanciloti; Michael Nerney; Emily Hays; Chet Robson; Nalini Chandar
Journal:  Exp Cell Res       Date:  2012-03-03       Impact factor: 3.905

2.  Developmental expression of Drosophila Wiskott-Aldrich Syndrome family proteins.

Authors:  Evelyn Rodriguez-Mesa; Maria Teresa Abreu-Blanco; Alicia E Rosales-Nieves; Susan M Parkhurst
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

3.  Age-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene.

Authors:  Bo Chang; Md Nawajes A Mandal; Venkata R M Chavali; Norman L Hawes; Naheed W Khan; Ronald E Hurd; Richard S Smith; Muriel L Davisson; Laura Kopplin; Barbara E K Klein; Ronald Klein; Sudha K Iyengar; John R Heckenlively; Radha Ayyagari
Journal:  Hum Mol Genet       Date:  2008-09-18       Impact factor: 6.150

Review 4.  Protein partners of deubiquitinating enzymes.

Authors:  Karen H Ventii; Keith D Wilkinson
Journal:  Biochem J       Date:  2008-09-01       Impact factor: 3.857

Review 5.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

6.  Identification and characterization of a novel Mdm2 splice variant acutely induced by the chemotherapeutic agents adriamycin and actinomycin D.

Authors:  Nathan H Lents; Leroy W Wheeler; Joseph J Baldassare; Brian David Dynlacht
Journal:  Cell Cycle       Date:  2008-03-24       Impact factor: 4.534

Review 7.  The Role of JMY in p53 Regulation.

Authors:  Omanma Adighibe; Francesco Pezzella
Journal:  Cancers (Basel)       Date:  2018-05-31       Impact factor: 6.639

8.  JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues.

Authors:  Omanma Adighibe; Helen Turley; Russell Leek; Adrian Harris; Amanda S Coutts; Nick La Thangue; Kevin Gatter; Francesco Pezzella
Journal:  Virchows Arch       Date:  2014-10-04       Impact factor: 4.064

Review 9.  Updates on p53: modulation of p53 degradation as a therapeutic approach.

Authors:  A Dey; C S Verma; D P Lane
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.